{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 32,
  "pageCount": 44,
  "prevPage": 31,
  "nextPage": 33,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a side-by-side comparison layout to detail patient cohorts and treatment regimens for different indications.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/32",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-32",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.34,
        "x": 0.15,
        "y": 0.38
      },
      "kind": "list",
      "text": "Total patients (n = 100)\nMelanoma: PD1 failure – (n = 40) Q2W\nNSCLC: PD1, EGFR or ALK failure – (n = 60) Q2W or 3Q4W\nMonotherapy and Combination with PD-1/L1\nUse to determine TmPS cut-off and potential registrational study design",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11e83da0-bfff-450e-9973-472004a48602",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.34,
        "x": 0.55,
        "y": 0.38
      },
      "kind": "list",
      "text": "Total patients (n = 40)\nSCCHN: Prior treatment with a PD-1/L1 inhibitor either administered alone (n = 20) or in combination with Platinum (n = 20) – Q2W\nMonotherapy\nUse to determine TmPS cut-off and potential registrational study design",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3c00fc9-39a3-4a03-8180-b404487e29f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.14,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Phase 2 – Melanoma / NSCLC",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40961ec9-62cf-4d92-9551-ffc4837f6a31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.36,
        "x": 0.54,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Phase 2 – SCCHN",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "476fb8da-e4ac-4c16-869f-2462b05f0598",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Phase 2 study design with BA3021 (Ozuriftamab Vedotin) in refractory patients for each indication: Melanoma, NSCLC and SCCHN",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87c30ffa-c66a-4b0f-a5c3-5381a01365ac",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}